The National Health Insurance Administration recently announced the results of the adjustment of the National Medical Insurance Drug List in 2023. This year is the sixth consecutive year that the National Medical Insurance Catalogue has been adjusted, with a total of 126 new drugs and 1 drug being transferred out of the catalogue, with an average reduction of more than 60% for drugs that have been successfully negotiated or bided.
After this round of adjustment, the total number of drugs in the new version of the catalogue has reached 3,088. Among them, there are 1,698 kinds of Western medicines and 1,390 kinds of Chinese patent medicinesThere are still 892 kinds of Chinese medicine decoction pieces. What are the drugs in the clinical field?Li Wenyan, director of the Department of Clinical Pharmacy of Gongli Hospital, introduced that the newly included drugs in the medical insurance drug list cover many fields, including anti-tumor drugs, a variety of chronic disease drugs, and antiviral drugs, and they are all currently needed in clinical practice, "For example, more than 20 kinds of anti-tumor drugs have been added this time, and Huatang Ningduogliatin tablets and other drugs have been added to diabetes drugs this time, which are drugs used by many patients in the clinical field at their own expense." ”
The reporter learned that the National Health Insurance Administration has carried out the adjustment of the drug catalog for 6 consecutive years, and a total of 744 drugs have been added to the national medical insurance drug catalog, and a number of drugs with indefinite efficacy, clinical abuse or eliminated drugs have been transferred out of the catalog. Commonly used drugs** have decreased significantly, and the level of drug protection for major diseases and special populations has been greatly improved.
Li Wenyan said: "The average decline in the national drug ** is currently calculated to be more than 60%, and the largest decline in the variety has even reached 90%. For example, Pudong's local innovative drug, Huatang Ningduogliatin tablets in the field of diabetes, is currently in clinical use in our hospital, and the self-paid stage is 15 pieces, and after being included in the medical insurance this time, it will drop to more than 5 pieces, a decrease of 60% to 70%. I think it is very beneficial for patients to reduce the cost of medication, because it is a long-term medication for chronic diseases. There is another domestic anti-new crown small molecule drug, Xenoxin, which is currently priced at 670 yuan in the clinic, and this time it has entered the medical insurance, and the price is less than 480 yuan. Most of the patients we face are covered by medical insurance, and we will take measures to encourage patients and clinical use of innovative drugs and drugs in the medical insurance catalog, so in the process of implementing innovative drugs, we will listen to clinical opinions, hold pharmaceutical affairs meetings in a timely manner, and introduce innovative drugs according to their needs in a timely manner to ensure clinical use. ”
The National Health Insurance Administration said that this year's catalogue adjustment has tilted the whole process from review to negotiation to innovative drugs. Among them, 38 innovative drugs in Shanghai have been successfully negotiated and included in the national medical insurance catalog, a record high, and a payment standard formation mechanism that basically covers the whole life cycle of new drugs has been initially established to increase support for pharmaceutical innovation.
The proportion of innovative drugs included in the medical insurance has increased in recent years, and among the domestic drugs added to the medical insurance catalogue this time, joint ventures and local innovative drugs have increased significantly. Including Huatangning, etc., it can immediately enter the clinical trial after being on the market for more than a year, and it has also entered the scope of medical insurance payment, which has a promoting effect on the research and development of the entire innovative drug. Therefore, in the whole circulation link, as the last link of drug use, clinical use is also actively introducing drugs in accordance with national policies. Li Wenyan said.
The new version of the National Medical Insurance Drug Catalogue will be officially implemented from next year, and the Shanghai medical insurance department will promote the implementation of new drugs in major hospitals in Shanghai as soon as possible. The list of medical insurance drugs and the allocation of drugs negotiated by the national medical insurance can be queried through the official website of the National Health Insurance Administration.
Text: Li Li.
Photo: Min Di.
Editor: Jiang Tianyao* *Please indicate that it is from the official WeChat of Pudong Release
A new road will be built here in Pudong, and the planning plan is being announced, see details for detailsMultiple measures to ensure the safety of winter driving, Pudong public transport enterprises do so